Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haplo-Cord HSCT for AML and MDS
NCT07588360Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Overall Survival at 3 years. Started Oct 2025; status: recruiting.
02
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07588360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07588360.